Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05984277




Registration number
NCT05984277
Ethics application status
Date submitted
2/08/2023
Date registered
9/08/2023
Date last updated
27/06/2024

Titles & IDs
Public title
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Scientific title
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
Secondary ID [1] 0 0
2023-000056-38
Secondary ID [2] 0 0
D798AC00001
Universal Trial Number (UTN)
Trial acronym
eVOLVE-Lung02
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Non-small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Volrustomig
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Carboplatin
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Pemetrexed

Experimental: Arm 1 - Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion

Active comparator: Arm 2 - Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion


Treatment: Drugs: Volrustomig
Volrustomig

Treatment: Drugs: Pembrolizumab
Pembrolizumab

Treatment: Drugs: Carboplatin
Carboplatin

Treatment: Drugs: Paclitaxel
Paclitaxel

Treatment: Drugs: Pemetrexed
Pemetrexed
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1)
Timepoint [1] 0 0
Up to approximately 6 years
Primary outcome [2] 0 0
Overall Survival (OS), in PD-L1-negative participants.
Timepoint [2] 0 0
Up to approximately 6 years
Secondary outcome [1] 0 0
PFS (using BICR assessments according to RECIST 1.1)
Timepoint [1] 0 0
Up to approximately 6 years
Secondary outcome [2] 0 0
OS
Timepoint [2] 0 0
Up to approximately 6 years
Secondary outcome [3] 0 0
PFS (using Investigator assessments according to RECIST 1.1)
Timepoint [3] 0 0
Up to approximately 6 years
Secondary outcome [4] 0 0
Overall Response Rate (ORR)
Timepoint [4] 0 0
Up to approximately 6 years
Secondary outcome [5] 0 0
Duration of Response (DoR)
Timepoint [5] 0 0
Up to approximately 6 years
Secondary outcome [6] 0 0
PFS2
Timepoint [6] 0 0
Up to approximately 6 years
Secondary outcome [7] 0 0
Concentration of volrustomig in serum and PK parameters
Timepoint [7] 0 0
Up to approximately 6 years
Secondary outcome [8] 0 0
Presence of ADAs against volrustomig in serum
Timepoint [8] 0 0
Up to approximately 6 years
Secondary outcome [9] 0 0
Time-To-Deterioration (TTD) in physical functioning
Timepoint [9] 0 0
Up to approximately 6 years
Secondary outcome [10] 0 0
TTD of lung cancer symptoms
Timepoint [10] 0 0
Up to approximately 6 years

Eligibility
Key inclusion criteria
Key

* Histologically or cytologically documented squamous or non-squamous NSCLC.
* Stage IV NSCLC (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2016), not amenable to curative surgery or radiation.
* Absence of sensitizing EGFR mutations and ALK and ROS1 rearrangements.
* Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted first-line therapies.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. Rare subtypes are excluded.
* Spinal cord compression.
* Symptomatic brain metastases. Brain metastases may be treated or untreated, but participants must be asymptomatic and off steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment.
* History of another primary malignancy except for:

1. Malignancy treated with curative intent with no known active disease = 2 years before the first dose of study intervention and of low potential risk for recurrence.
2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
3. Adequately treated carcinoma in situ without evidence of disease.
* As judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/10/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/05/2029
Actual
Sample size
Target
900
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Clayton
Recruitment hospital [2] 0 0
Research Site - Fitzroy
Recruitment hospital [3] 0 0
Research Site - Heidelberg
Recruitment hospital [4] 0 0
Research Site - South Brisbane
Recruitment hospital [5] 0 0
Research Site - Sydney
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
NSW 2145 - Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Delaware
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Mississippi
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Caba
Country [26] 0 0
Argentina
State/province [26] 0 0
Ciudad de Córdoba
Country [27] 0 0
Argentina
State/province [27] 0 0
Córdoba
Country [28] 0 0
Argentina
State/province [28] 0 0
La Plata
Country [29] 0 0
Argentina
State/province [29] 0 0
Rosario
Country [30] 0 0
Austria
State/province [30] 0 0
Linz
Country [31] 0 0
Austria
State/province [31] 0 0
Wels
Country [32] 0 0
Belgium
State/province [32] 0 0
Aalst
Country [33] 0 0
Belgium
State/province [33] 0 0
Antwerpen
Country [34] 0 0
Belgium
State/province [34] 0 0
Gent
Country [35] 0 0
Brazil
State/province [35] 0 0
Barretos
Country [36] 0 0
Brazil
State/province [36] 0 0
Curitiba
Country [37] 0 0
Brazil
State/province [37] 0 0
Florianópolis
Country [38] 0 0
Brazil
State/province [38] 0 0
Fortaleza
Country [39] 0 0
Brazil
State/province [39] 0 0
Natal
Country [40] 0 0
Brazil
State/province [40] 0 0
Porto Alegre
Country [41] 0 0
Brazil
State/province [41] 0 0
Rio De Janeiro
Country [42] 0 0
Brazil
State/province [42] 0 0
Santa Cruz do Sul
Country [43] 0 0
Brazil
State/province [43] 0 0
Sao Paulo
Country [44] 0 0
Canada
State/province [44] 0 0
Alberta
Country [45] 0 0
Canada
State/province [45] 0 0
Manitoba
Country [46] 0 0
Canada
State/province [46] 0 0
Nova Scotia
Country [47] 0 0
Canada
State/province [47] 0 0
Ontario
Country [48] 0 0
Canada
State/province [48] 0 0
Quebec
Country [49] 0 0
Canada
State/province [49] 0 0
Chicoutimi
Country [50] 0 0
China
State/province [50] 0 0
Chengdu
Country [51] 0 0
China
State/province [51] 0 0
Wuhan
Country [52] 0 0
Czechia
State/province [52] 0 0
Olomouc
Country [53] 0 0
Czechia
State/province [53] 0 0
Ostrava - Vitkovice
Country [54] 0 0
Czechia
State/province [54] 0 0
Praha 2
Country [55] 0 0
Czechia
State/province [55] 0 0
Praha
Country [56] 0 0
France
State/province [56] 0 0
Angers
Country [57] 0 0
France
State/province [57] 0 0
Avignon
Country [58] 0 0
France
State/province [58] 0 0
Bayonne
Country [59] 0 0
France
State/province [59] 0 0
Bordeaux
Country [60] 0 0
France
State/province [60] 0 0
Caen
Country [61] 0 0
France
State/province [61] 0 0
Lille
Country [62] 0 0
France
State/province [62] 0 0
Limoges
Country [63] 0 0
France
State/province [63] 0 0
Marseille
Country [64] 0 0
France
State/province [64] 0 0
Montpellier
Country [65] 0 0
France
State/province [65] 0 0
Paris Cedex 5
Country [66] 0 0
France
State/province [66] 0 0
Quimper cedex
Country [67] 0 0
France
State/province [67] 0 0
Reims
Country [68] 0 0
France
State/province [68] 0 0
Saint-Malo
Country [69] 0 0
France
State/province [69] 0 0
Strasbourg Cedex
Country [70] 0 0
France
State/province [70] 0 0
Suresnes
Country [71] 0 0
Germany
State/province [71] 0 0
Berlin-Zehlendorf
Country [72] 0 0
Germany
State/province [72] 0 0
Bonn
Country [73] 0 0
Germany
State/province [73] 0 0
Dresden
Country [74] 0 0
Germany
State/province [74] 0 0
Essen
Country [75] 0 0
Germany
State/province [75] 0 0
Gauting
Country [76] 0 0
Germany
State/province [76] 0 0
Georgsmarienhuette
Country [77] 0 0
Germany
State/province [77] 0 0
Halle
Country [78] 0 0
Germany
State/province [78] 0 0
Hamburg
Country [79] 0 0
Germany
State/province [79] 0 0
Heidelberg
Country [80] 0 0
Germany
State/province [80] 0 0
Immenhausen
Country [81] 0 0
Germany
State/province [81] 0 0
Koblenz
Country [82] 0 0
Germany
State/province [82] 0 0
Nürnberg
Country [83] 0 0
Germany
State/province [83] 0 0
Tuebingen
Country [84] 0 0
Hungary
State/province [84] 0 0
Budapest
Country [85] 0 0
Hungary
State/province [85] 0 0
Deszk
Country [86] 0 0
Hungary
State/province [86] 0 0
Gyöngyös - Mátraháza
Country [87] 0 0
Hungary
State/province [87] 0 0
Gyor
Country [88] 0 0
Hungary
State/province [88] 0 0
Pécs
Country [89] 0 0
Hungary
State/province [89] 0 0
Szekszárd
Country [90] 0 0
Hungary
State/province [90] 0 0
Székesfehérvár
Country [91] 0 0
Hungary
State/province [91] 0 0
Törökbálint
Country [92] 0 0
India
State/province [92] 0 0
Bengaluru
Country [93] 0 0
India
State/province [93] 0 0
Delhi
Country [94] 0 0
India
State/province [94] 0 0
Hyderabad
Country [95] 0 0
India
State/province [95] 0 0
Kolkata
Country [96] 0 0
India
State/province [96] 0 0
Mysuru
Country [97] 0 0
India
State/province [97] 0 0
Nagpur
Country [98] 0 0
India
State/province [98] 0 0
Nashik
Country [99] 0 0
India
State/province [99] 0 0
New Delhi
Country [100] 0 0
India
State/province [100] 0 0
Varanasi
Country [101] 0 0
Italy
State/province [101] 0 0
Bari
Country [102] 0 0
Italy
State/province [102] 0 0
Bergamo
Country [103] 0 0
Italy
State/province [103] 0 0
Catanzaro
Country [104] 0 0
Italy
State/province [104] 0 0
Milano
Country [105] 0 0
Italy
State/province [105] 0 0
Padova
Country [106] 0 0
Italy
State/province [106] 0 0
Parma
Country [107] 0 0
Italy
State/province [107] 0 0
Pavia
Country [108] 0 0
Italy
State/province [108] 0 0
Ravenna
Country [109] 0 0
Italy
State/province [109] 0 0
Roma
Country [110] 0 0
Japan
State/province [110] 0 0
Fukuoka-shi
Country [111] 0 0
Japan
State/province [111] 0 0
Kashiwa
Country [112] 0 0
Japan
State/province [112] 0 0
Kawasaki-shi
Country [113] 0 0
Japan
State/province [113] 0 0
Nagoya-shi
Country [114] 0 0
Japan
State/province [114] 0 0
Osakasayama-shi
Country [115] 0 0
Japan
State/province [115] 0 0
Yokohama-shi
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Cheongju-si
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Incheon
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Jinju-si
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Seoul
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Suwon-si
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Suwon
Country [122] 0 0
Mexico
State/province [122] 0 0
Ciudad de México
Country [123] 0 0
Mexico
State/province [123] 0 0
Culiacan
Country [124] 0 0
Mexico
State/province [124] 0 0
Guadalajara
Country [125] 0 0
Mexico
State/province [125] 0 0
Mexico City
Country [126] 0 0
Mexico
State/province [126] 0 0
Monterrey
Country [127] 0 0
Mexico
State/province [127] 0 0
Naucalpan
Country [128] 0 0
Netherlands
State/province [128] 0 0
Amsterdam
Country [129] 0 0
Netherlands
State/province [129] 0 0
Groningen
Country [130] 0 0
Netherlands
State/province [130] 0 0
Nieuwegein
Country [131] 0 0
Netherlands
State/province [131] 0 0
Tilburg
Country [132] 0 0
Poland
State/province [132] 0 0
Lublin
Country [133] 0 0
Poland
State/province [133] 0 0
Poznan
Country [134] 0 0
Poland
State/province [134] 0 0
Przemysl
Country [135] 0 0
Poland
State/province [135] 0 0
Rzeszów
Country [136] 0 0
Poland
State/province [136] 0 0
Szklarska Poreba
Country [137] 0 0
Poland
State/province [137] 0 0
Tomaszów Mazowiecki
Country [138] 0 0
Poland
State/province [138] 0 0
Torun
Country [139] 0 0
Poland
State/province [139] 0 0
Warszawa
Country [140] 0 0
Poland
State/province [140] 0 0
Lódz
Country [141] 0 0
Slovakia
State/province [141] 0 0
Banska Bystrica
Country [142] 0 0
Slovakia
State/province [142] 0 0
Bratislava
Country [143] 0 0
Slovakia
State/province [143] 0 0
Kosice
Country [144] 0 0
Slovakia
State/province [144] 0 0
Trnava
Country [145] 0 0
South Africa
State/province [145] 0 0
Amanzimtoti
Country [146] 0 0
South Africa
State/province [146] 0 0
Bloemfontein
Country [147] 0 0
South Africa
State/province [147] 0 0
George
Country [148] 0 0
South Africa
State/province [148] 0 0
Johannesburg
Country [149] 0 0
South Africa
State/province [149] 0 0
Parktown
Country [150] 0 0
South Africa
State/province [150] 0 0
Pietermaritzburg
Country [151] 0 0
South Africa
State/province [151] 0 0
Pretoria
Country [152] 0 0
South Africa
State/province [152] 0 0
Rondebosch
Country [153] 0 0
South Africa
State/province [153] 0 0
Soweto
Country [154] 0 0
Spain
State/province [154] 0 0
Alicante
Country [155] 0 0
Spain
State/province [155] 0 0
Barcelona
Country [156] 0 0
Spain
State/province [156] 0 0
Bilbao (Vizcaya)
Country [157] 0 0
Spain
State/province [157] 0 0
Madrid
Country [158] 0 0
Spain
State/province [158] 0 0
Málaga
Country [159] 0 0
Spain
State/province [159] 0 0
Palma
Country [160] 0 0
Taiwan
State/province [160] 0 0
Hsinchu
Country [161] 0 0
Taiwan
State/province [161] 0 0
Kaohsiung
Country [162] 0 0
Taiwan
State/province [162] 0 0
Tainan
Country [163] 0 0
Taiwan
State/province [163] 0 0
Taipei City
Country [164] 0 0
Taiwan
State/province [164] 0 0
Taipei
Country [165] 0 0
Taiwan
State/province [165] 0 0
Yunlin
Country [166] 0 0
Thailand
State/province [166] 0 0
Lampang
Country [167] 0 0
Thailand
State/province [167] 0 0
Muang
Country [168] 0 0
Thailand
State/province [168] 0 0
Songkhla
Country [169] 0 0
Turkey
State/province [169] 0 0
Ankara
Country [170] 0 0
Turkey
State/province [170] 0 0
Antalya
Country [171] 0 0
Turkey
State/province [171] 0 0
Diyarbakir
Country [172] 0 0
Turkey
State/province [172] 0 0
Istanbul
Country [173] 0 0
Turkey
State/province [173] 0 0
Izmir
Country [174] 0 0
Turkey
State/province [174] 0 0
Pamukkale
Country [175] 0 0
Turkey
State/province [175] 0 0
Çankaya
Country [176] 0 0
United Kingdom
State/province [176] 0 0
Birmingham
Country [177] 0 0
United Kingdom
State/province [177] 0 0
Blackpool
Country [178] 0 0
United Kingdom
State/province [178] 0 0
Bury St Edmunds
Country [179] 0 0
United Kingdom
State/province [179] 0 0
Colchester
Country [180] 0 0
United Kingdom
State/province [180] 0 0
London
Country [181] 0 0
United Kingdom
State/province [181] 0 0
Truro

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \< 50%.
Trial website
https://clinicaltrials.gov/study/NCT05984277
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
information.center@astrazeneca.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05984277